Genetic Signatures

Genetic Signatures Equity Turnover

The Equity Turnover of Genetic Signatures (GSS.AX) as of Nov 3, 2026 is 0.40. In the previous year, Equity Turnover was 0.32 — a change of 27.46% (higher).

Equity Turnover

0.40

YoY

27.46%

Last updated:

Equity Turnover of Genetic Signatures is 2026 0.40 . Equity Turnover of Genetic Signatures was 2025 0.32 . It decreases by 27.46% higher compared to the previous year.

The Genetic Signatures Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2019
0.66 AUD
Jan 1, 2020
0.25 AUD
Jan 1, 2021
0.57 AUD
Jan 1, 2022
0.65 AUD
Jan 1, 2023
0.39 AUD
Jan 1, 2024
0.16 AUD
Jan 1, 2025
0.32 AUD
Jan 1, 2026
0.40 AUD
The Genetic Signatures Equity Turnover history
YEAREquity TurnoverYoY
0.40+27.46%
0.32+98.59%
0.16-59.51%
0.39-38.93%
0.65+12.75%
0.57+133.76%
0.25-63.10%
0.66+78.32%
0.37+51.27%
0.25-64.70%
0.70+372.05%
0.15+85.03%
0.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Equity Turnover of Genetic Signatures is 0.40 in 2026.

Equity Turnover of Genetic Signatures changed from 0.32 to 0.40, representing a 27.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Genetic Signatures

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Genetic Signatures